Pulmonary sarcoid-like granulomatosis induced by nivolumab

British Journal of Dermatology

Volumn 176, Issue 4, 2017, Pages 1060-1063

  Montaudie H ^a   Pradelli, J ^b   Passeron, T ^a,c   Lacour, J P ^a   Leroy, S ^b  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b PASTEUR HOSPITAL   (France)

^c CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COBIMETINIB; NIVOLUMAB; PREDNISONE; VEMURAFENIB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; BRONCHUS BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CD4 CD8 RATIO; CORTICOSTEROID THERAPY; COUGHING; CYBERKNIFE; DISEASE COURSE; DRUG SAFETY; DRY EYE; DYSPNEA; FEVER; HEMOPTYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFUSION RELATED REACTION; LEUKOCYTE DIFFERENTIAL COUNT; LUNG GRANULOMATOSIS; LUNG INFILTRATE; LUNG LAVAGE; LUNG NODULE; LUNG SARCOIDOSIS; LUNG TOXICITY; LYMPHOCYTE COUNT; MALE; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PAROTITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; CHEMICALLY INDUCED; CHURG STRAUSS SYNDROME; DIAGNOSTIC IMAGING; LUNG DISEASE; MELANOMA; SARCOIDOSIS; SKIN NEOPLASMS; X-RAY COMPUTED TOMOGRAPHY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHURG-STRAUSS SYNDROME; HUMANS; LUNG DISEASES; MALE; MELANOMA; MIDDLE AGED; SARCOIDOSIS; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85006982967     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14808     Document Type: Article

References (15)

1. Larkin J, Ascierto PA, Dréno B et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371:1867–76.
2. Ascierto PA, Marincola FM, Atkins MB. What's new in melanoma? Combination! J Transl Med 2015; 13:213.
3. Long GV, Stroyakovskiy D, Gogas H et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015; 386:444–51.
4. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711–23.
5. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320–30.
6. Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16:375–84.
7. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373:123–35.
8. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23–34.
9. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443–54.
10. Nishino M, Sholl LM, Hodi FS et al. Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 2015; 373:288–90.
11. Beutler BD, Cohen PR. Sarcoidosis in melanoma patients: case report and literature review. Cancers 2015; 7:1005–21.
12. Berthod G, Lazor R, Letovanec I et al. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol 2012; 30:e156–9.
13. Cousin S, Toulmonde M, Kind M et al. Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab. Ann Oncol 2016; 27:1178–9.
14. + T Cells During an Allogeneic Mixed Lymphocyte Reaction (MLR) (Medarex Study No. MDX-1106-026-R). Document Control no. 930046581. New York: Bristol-Myers Squibb, 2006.
15. Freeman-Keller M, Kim Y, Cronin H et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2016; 22:886–94.